Neumora Therapeutics, Inc.
NMRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NMRA
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain diseases, with its lead candidate NMRA-335140 in Phase 3 trials for major depressive disorder.
Key risk: Clinical trial risks
BioSniper Score
Based on 6 of 6 signals
Market Cap
$261.2M
Cash Runway
9.1 moLead Asset
navacaprant (Phase 3)
Next Catalyst
Phase3_Topline · Jun 1, 2027Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 7 clinical trials · 1 catalyst for Neumora Therapeutics, Inc..
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain diseases, with its lead candidate NMRA-335140 in Phase 3 trials for major depressive disorder.
- Cash and equivalents of $116.8M as of 2026-06-30 [sec].
- Net loss of -$43.1M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $103.9M and total debt of $112.9M as of 2026-06-30 [sec].
- Lead product candidate NMRA-335140 is in a Phase 3 long-term study for major depressive disorder [catalyst_timeline].
- The company has not yet completed development or commercialization of any product candidate [sec_mda · as of 2026-03-30].
What works
- Cash position of $116.8M as of 2026-06-30 provides near-term funding for ongoing clinical trials [sec].
- Lead candidate NMRA-335140 has advanced to Phase 3, indicating progress in clinical development [catalyst_timeline].
- The company is focused on a high-need therapeutic area (brain diseases) with potential for significant market opportunity [sec_mda · as of 2026-03-30].
What to weigh
- The company has a history of net losses, with a net loss of -$43.1M for the period ended 2026-06-30 [sec].
- Total debt of $112.9M as of 2026-06-30 exceeds shareholders' equity, indicating financial leverage [sec].
- No product candidates have been approved or commercialized, and the company faces typical drug development risks including clinical trial delays and regulatory hurdles [sec_mda · as of 2026-08-14].
- Future capital requirements are uncertain and depend on many factors, including trial costs and regulatory outcomes [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Company has not completed development or commercialization of any product candidate
“We have not completed development and commercialization of any of our product candidates with most still being in relatively early development.”
SEC MD&A · March 30, 2026
Future capital requirements depend on many factors including clinical trial costs
“our future capital requirements will depend on many factors, including: • the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2027-06-01 · Phase3_Topline — Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep — Topline results from the Phase 3 long-term study of NMRA-335140 for major depressive disorder are expected, which will inform the drug's safety and efficacy profile.
Risks & what to watch (4)›
Key risks
- Clinical trial risks — Unforeseen expenses, delays, or failures in clinical trials could adversely affect business [sec_mda · as of 2026-08-14].
- Regulatory approval uncertainty — No product candidates have received regulatory approval; approval process is costly and uncertain [sec_mda · as of 2026-03-30].
- Financial leverage and losses — Total debt of $112.9M exceeds equity of $103.9M; net losses continue [sec].
- Capital requirements — Future capital needs are uncertain and may require additional financing [sec_mda · as of 2026-05-07].
What to watch
- Phase 3 topline data for NMRA-335140 expected around 2027-06-01 [catalyst_timeline].
- Cash burn rate and any updates on financing or capital position [sec].
- Progress of other preclinical or clinical candidates in the pipeline [sec_mda · as of 2026-03-30].
- Regulatory interactions or updates on NMRA-335140's development path [sec_mda · as of 2026-05-07].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Neumora Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neumora Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.1 months
D/E 1.81 · 0% dilution
Lead: Phase 3
7 candidates
1 upcoming, next in ~275d
0 buys · 11 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 4.3%
- Days to cover
- 3.8
- Shares short
- 4,469,003
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NMRA short interestFrequently asked questions
What is the AI investment thesis for Neumora Therapeutics, Inc.?
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain diseases, with its lead candidate NMRA-335140 in Phase 3 trials for major depressive disorder.
What is Neumora Therapeutics, Inc.'s lead drug candidate?
Neumora Therapeutics, Inc.'s most advanced tracked candidate is navacaprant (Phase 3) for major depressive disorder (MDD).
What is Neumora Therapeutics, Inc.'s next catalyst?
Neumora Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep" — expected June 1, 2027.
Who is the CEO of Neumora Therapeutics, Inc.?
Mr. Paul L. Berns is the chief executive officer of Neumora Therapeutics, Inc. (NMRA).
Where is Neumora Therapeutics, Inc. headquartered?
Neumora Therapeutics, Inc. (NMRA) is headquartered in Watertown, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.